US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

34.17

+0.60801.81%

Post-market: 34.170.00000.00%16:10 EDT

Volume:176

Turnover:6K

Market Cap:13.67M

PE:- -

High:34.17

Open:33.56

Low:34.17

Close:33.56

52wk High:34.86

52wk Low:25.79

Shares:400.00K

Float Shares:400.00K

Volume Ratio:0.31

T/O Rate:0.04%

Dividend:0.08

Dividend Rate:0.23%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Johnson & Johnson Says Subcutaneous Cancer Treatment Study Shows Low Rates Across Key Events, Discontinuation

MT Newswires Live

Barclays downgrades Scholar Rock on valuation after FDA approval

Jiangsu Hengrui Secures Green Light for HRS-4139 Tablet Clinical Trials

Huangjia Ruangan Granules Receives Approval for Phase III Clinical Trial in Chronic Hepatitis B Fibrosis Treatment

Shenyang Xingqi Pharma Gains NMPA Approval to Initiate Clinical Trials for SQ-25012 Injection in Thyroid Eye Disease

港股市场动态：海西新药股价上扬，新药申请获受理推进

JNJ Reports Low Rates of Treatment-Related Events for Rybrevant Faspro Plus Lazcluze at Wclc 2026

J&J - Fewer than 1% Discontinue Rybrevant Faspro Plus Lazcluze Due to Treatment-Related Events at One Year

THOMSON REUTERS

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

Bio-Techne Supplements Merger Proxy Amid Shareholder Litigation

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS

Merck & Co Exec Says Potential 340B and Policy Evolutions Would Create Tailwinds but are not Material to the Business - Morgan Stanley Conf

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/BMED/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":34.1689,"timestamp":1789675200000,"preClose":33.5609,"halted":0,"volume":176,"hourTrading":{"tag":"盘后","latestPrice":34.1689,"preClose":34.1689,"latestTime":"16:10 EDT","volume":8,"amount":273.3512,"timestamp":1789675803872,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.018116319884151025,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"Post-Mkt","change":0.608,"latestTime":"09-17 18:21:40 EDT","open":33.5609,"high":34.1689,"low":34.1689,"amount":6029,"amplitude":0,"askPrice":50.97,"askSize":200,"bidPrice":16.99,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789689600000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":33.5609,"sharesOutstanding":360000,"nav":33.339378,"aum":13335751.2,"dividendRate":0.002333,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.1689,"preClose":34.1689,"latestTime":"16:10 EDT","volume":8,"amount":273.3512,"timestamp":1789675803872,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.305238,"impliedVol":0.0628,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.305238,"shares":400000,"dividePrice":0.0797,"high":34.1689,"amplitude":0,"preClose":33.5609,"low":34.1689,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":34.1689,"eps":0,"divideRate":0.002333,"volume":176,"delay":0,"ttmEps":0,"open":33.5609,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":32.8027,"twentyDayClose":34.7939,"sixtyDayClose":28.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667623951","title":"LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623951","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667623951?lang=en_us&edition=fundamental","pubTime":"2026-09-15 22:52","pubTimestamp":1789483971,"startTime":"0","endTime":"0","summary":"LIVE MARKETS-Autumn in New York: Factory expansion slows, input prices at multi-year highs - Empire StateMain US equity indexes red; Dow leads losses down ~1%Consumer Discretionary is weakest S&P 500 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL6N4570XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905037.USD","LU0203347892.USD","BK4581","LU1121112475.USD","LU1066053197.SGD","LU0320765646.SGD","IE00BBT3K403.USD","LU0426412945.USD","LU1983299246.USD","LU0122379950.USD","IHE","LU1914381329.SGD","LU1929549753.HKD","LU2023250330.USD","LU2592432038.USD","LU2750360997.AUD","IE00BSNM7G36.USD","CTNM","LU2236285917.USD","FHLC","RXL","VHT","GDOC","LU0787776722.HKD","IE000M9KFDE8.USD","IYH","XLV","LU1989771016.USD","BK4550","LU2347655156.SGD","LU1894683348.USD","LU0114720955.EUR","JDOC","LU0964807845.USD","LU1629891620.HKD","MEDX","LU2487616109.SGD","SG9999013999.USD","LU1496350502.SGD","TRUH","IE000WAW04H5.SGD","FTXH","LU0345769128.USD","BMED","IXJ","LU2430703251.USD","IE0001KFT4U8.USD","PJP","LU0689472784.USD","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628755","title":"LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628755","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667628755?lang=en_us&edition=fundamental","pubTime":"2026-09-15 22:27","pubTimestamp":1789482448,"startTime":"0","endTime":"0","summary":"LIVE MARKETS-US stock indexes swing lower as oil, yields jumpMain US equity indexes red; Dow leads losses down ~1%Consumer Discretionary is weakest S&P 500 sector; energy sole gainerEuro STOXX 600 ind","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL6N4570WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905037.USD","LU0203347892.USD","LU1221951129.SGD","LU0820562030.AUD","LU1066051811.HKD","LU2456880835.USD","LU1674673428.USD","IE00BLSP4239.USD","LU1585245621.USD","BK4592","IHE","LU0795875169.SGD","LU2417539215.USD","IE000F7OJYX1.SGD","LU2471134523.USD","LU2592432038.USD","SG9999002224.SGD","LU2471134952.CNY","IE00BVYPNV92.GBP","CTNM","LU2236285917.USD","LU2505996509.AUD","FHLC","RXL","VHT","GDOC","IE000BZT7R73.USD","XLV","IYH","LU1043141396.HKD","IE00BZ1G4Q59.USD","LU1145028129.USD","JDOC","MEDX","TRUH","LU2487616109.SGD","FTXH","LU1059921491.USD","LU0345769128.USD","SG9999001176.SGD","LU0820561818.USD","LU2112291526.USD","LU2468319806.SGD","BMED","BK4568","LU2896262040.SGD","IXJ","PJP","LU0057025933.USD","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667645017","title":"Johnson & Johnson Says Subcutaneous Cancer Treatment Study Shows Low Rates Across Key Events, Discontinuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645017","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645017?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:09","pubTimestamp":1789466958,"startTime":"0","endTime":"0","summary":"Johnson & Johnson  said late Monday that early results from a phase 2b study of subcutaneous Rybrevant Faspro plus Lazcluze showed consistently low rates across key treatment-related events and discontinuation in certain non-small cell lung cancer patients.The trail covers patients with previously untreated advanced non-small cell lung cancer with common epidermal growth factor receptor mutations.At a median follow-up of 8.3 months, the majority of adverse events were grade 1 or 2, with no new safety signals, while only 8% of patients discontinued treatment due to adverse events.The study showed rash in 25% of patients, while administration-related reactions and venous thromboembolism were each reported in 3%.No patients discontinued due to administration-related reactions, while only 1% discontinued due to rash and venous thromboembolism, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1145028129.USD","LU1221951129.SGD","LU1674673428.USD","BK4534","LU0820562030.AUD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","LU1244550494.USD","LU1280957306.USD","LU0162691827.USD","JNJ","FHLC","LU0640476718.USD","LU1043141396.HKD","LU2471134879.HKD","LU2896262040.SGD","BK4585","SGXZ80539844.SGD","TRUH","IYH","IXJ","VHT","BK4581","LU0943347566.SGD","LU2347655156.SGD","LU2089984988.USD","XLV","MEDX","GDOC","PJP","BK4559","LU1894683348.USD","LU0210536198.USD","IHE","LU1718418525.SGD","LU0234570918.USD","LU1121112475.USD","LU2213496289.HKD","LU2471134796.USD","IE00B3T34201.USD","FTXH","LU2505996681.GBP","LU2403377893.USD","LU1732799900.SGD","LU1261432733.SGD","LU0289739343.SGD","RXL","LU0345769128.USD","BMED","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667643557","title":"Barclays downgrades Scholar Rock on valuation after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643557?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:10","pubTimestamp":1789463419,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSPA","BBP","TACU","MRNY","IEIH","IYH","BMED","TECB","IDNA","XLVX","LABU","PINK","LFSC","NVIB","MEDI","CDIG","PSCH","GDOC","GNMX","RSPH","IBB","TBXU","SYNB","FRTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151952155","title":"Jiangsu Hengrui Secures Green Light for HRS-4139 Tablet Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1151952155","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151952155?lang=en_us&edition=fundamental","pubTime":"2026-09-15 16:42","pubTimestamp":1789461741,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SH: 600276) has announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice from the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","LU2543165471.USD","LU1997245177.USD","LU2580892789.USD","IBBJ","LU1064131003.USD","LU2495084118.USD","BK0188","LU1969619763.USD","BK0028","LU1146622755.USD","BK1191","BMED","LU0359201612.USD","LU1255011170.USD","LU1997244956.HKD","LU1997245094.SGD","LU2097828474.EUR","LU2488822045.USD","LU2097828631.EUR","LU2097828714.EUR","BK0060","600276","LU0405327494.USD","LU0359201885.HKD","BK0012","MDTX","LU2289578879.USD","LU1328615791.USD","LU0405327148.USD","LU1820825898.SGD","LU2097828557.USD","LU2580892862.HKD","LU1781817850.SGD","IBBQ","BK0239","LU1655091616.SGD","LU2148510915.USD","PSYK","LU0359202008.SGD","LU1580142542.USD","01276","LU2328871848.SGD","LU1064130708.USD","LU2097828805.USD","LU1023057109.AUD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165786716","title":"Huangjia Ruangan Granules Receives Approval for Phase III Clinical Trial in Chronic Hepatitis B Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1165786716","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165786716?lang=en_us&edition=fundamental","pubTime":"2026-09-15 16:18","pubTimestamp":1789460304,"startTime":"0","endTime":"0","summary":"Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ) has announced that it recently received the Drug Clinical Trial Supplemental Application Approval Notice issued by the National Medical...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","IBBJ","300878","PSYK","IBBQ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106452599","title":"Shenyang Xingqi Pharma Gains NMPA Approval to Initiate Clinical Trials for SQ-25012 Injection in Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=1106452599","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106452599?lang=en_us&edition=fundamental","pubTime":"2026-09-15 15:58","pubTimestamp":1789459095,"startTime":"0","endTime":"0","summary":"Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) has announced that it recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSYK","BK0177","IBBQ","IBBJ","MDTX","BK0239","BMED","300573"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191881847","title":"港股市场动态：海西新药股价上扬，新药申请获受理推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1191881847","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191881847?lang=en_us&edition=fundamental","pubTime":"2026-09-15 14:52","pubTimestamp":1789455138,"startTime":"0","endTime":"0","summary":"港股市场上，海西新药 (02637)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBJ","IBBQ","MDTX","BK1191","BMED","02637","BK4588","BK4585","VXUS","KCAI","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667100618","title":"JNJ Reports Low Rates of Treatment-Related Events for Rybrevant Faspro Plus Lazcluze at Wclc 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2667100618","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667100618?lang=en_us&edition=fundamental","pubTime":"2026-09-15 11:03","pubTimestamp":1789441423,"startTime":"0","endTime":"0","summary":"BRIEF-JNJ Reports Low Rates Of Treatment-Related Events For Rybrevant Faspro Plus Lazcluze At Wclc 2026Sept 14 -Johnson & JohnsonJNJ.N:J&J - JNJ REPORTS LOW RATES OF TREATMENT-RELATED EVENTS FOR RYBREVANT FASPRO PLUS LAZCLUZE AT WCLC 2026J&J - FEWER THAN 1% DISCONTINUE RYBREVANT FASPRO PLUS LAZCLUZE DUE TO TREATMENT-RELATED EVENTS AT ONE YEARSource text: [ID:]Further company coverage:JNJ.N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN4560KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2456880835.USD","LU1061106388.HKD","GDOC","SG9999013999.USD","LU2129689605.HKD","LU1196500208.SGD","IHE","FTXH","VHT","LU0994945656.USD","BMED","LU1551013342.USD","LU0122379950.USD","LU0426412945.USD","LU2347655156.SGD","LU1778281490.HKD","LU0234570918.USD","LU0689472784.USD","IXJ","LU2213496289.HKD","BK4532","JDOC","LU0511384066.AUD","IE00B3T34201.USD","TRUH","FHLC","LU0058720904.USD","MEDX","SG9999001176.SGD","LU0057025933.USD","LU2236285917.USD","IYH","LU2403377893.USD","IE000SO60NU8.SGD","LU0069063385.USD","LU0203347892.USD","PJP","LU2750360641.GBP","LU1989771016.USD","RXL","LU0466842654.USD","LU0882574055.USD","LU0964807845.USD","LU0943347566.SGD","LU0234572021.USD","XLV","LU1291159041.SGD","LU1244550494.USD","LU2430703095.HKD","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667181756","title":"J&J - Fewer than 1% Discontinue Rybrevant Faspro Plus Lazcluze Due to Treatment-Related Events at One Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2667181756","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667181756?lang=en_us&edition=fundamental","pubTime":"2026-09-15 11:02","pubTimestamp":1789441334,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN4560KR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFXG1179.USD","IE0002270589.USD","IHE","LU1506573853.SGD","SG9999013999.USD","LU0912757837.SGD","XLV","FTXH","LU0943347566.SGD","LU2430703178.SGD","LU2236285917.USD","IYH","LU0122379950.USD","LU1894683348.USD","RXL","LU2430703251.USD","LU0070217475.USD","LU2023250330.USD","LU0345770308.USD","VHT","LU1280957306.USD","GDOC","IE00BVYPNW00.USD","LU2129689431.USD","IE00B2B36J28.USD","LU2756315318.SGD","BK4585","MEDX","BK4534","BK4533","JNJ","LU0683600562.USD","JDOC","IE00B42XCP33.USD","LU1291159041.SGD","LU1261432733.SGD","TRUH","BK4592","LU0053666078.USD","IE00B19Z3581.USD","PJP","FHLC","IE00B3T34201.USD","IXJ","LU1032955483.USD","LU0689472784.USD","LU1929549753.HKD","LU0466842654.USD","IE00BKVL7J92.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667310690","title":"RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667310690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667310690?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:46","pubTimestamp":1789436772,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Trung Huynh maintained a Hold rating on Merck & Company yesterday and set a price target of $150.00. Huynh covers the Healthcar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","SG9999002224.SGD","SG9999001176.SGD","LU2106854487.HKD","GDOC","SG9999014542.SGD","LU1923622614.USD","IE00B4R5TH58.HKD","LU2491050071.SGD","LU1066051811.HKD","LU1699723380.USD","FHLC","LU0289739699.SGD","LU1032466523.USD","LU2491050154.USD","LU0320765489.SGD","IHE","LU2023250504.SGD","LU0511384066.AUD","LU0868494617.USD","LU2433249047.HKD","LU1430594728.SGD","LU2361044865.SGD","LU1934455277.USD","LU0058720904.USD","LU1116320901.HKD","LU1585245621.USD","LU2491049909.HKD","LU0965509010.AUD","LU0130517989.USD","LU1162221912.USD","LU0823416689.USD","BK4534","LU0238689110.USD","LU0124676726.USD","LU0965508806.USD","LU0208291251.USD","LU2361045086.USD","BK4588","IE00B2B36J28.USD","LU0942090050.USD","LU1037948897.HKD","LU1917777945.USD","LU0057025933.USD","SGXZ57979304.SGD","BK4533","IE00B1BXHZ80.USD","LU0689626769.HKD","LU0965509101.SGD","VHT","LU1066051225.USD","LU1929549753.HKD","LU1057294990.SGD","LU0289739343.SGD","LU1061106388.HKD","LU2125909247.SGD","TRUH","LU1934455194.USD","LU0211331839.USD","LU1989772840.SGD","LU0265550359.USD","LU0006306889.USD","LU1023059063.AUD","SG9999001440.SGD","IE00BJJMRZ35.SGD","IE00BLSP4452.SGD","LU0234572021.USD","LU1989772923.USD","IYH","LU2468319806.SGD","LU1983299246.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0069063385.USD","IE00BBT3K403.USD","LU1934455863.HKD","LU0320765646.SGD","SG9999015358.SGD","LU2357627491.SGD","LU0868494708.USD","LU1291159041.SGD","RXL","BK4585","LU0648001328.SGD","SG9999014567.USD","SG9999015341.SGD","SG9999002232.USD","LU0098860793.USD","IE00BSNM7G36.USD","LU1066051498.USD","IE00BJT1NW94.SGD","LU1116320737.USD","LU1974910355.USD","LU2112291526.USD","LU2125154935.USD","PPH","LU0477156953.USD","LU1941712348.USD","SG9999013999.USD","IE000M9KFDE8.USD","LU1035773651.USD","LU0861579265.USD","JDOC","PAWZ","LU0265550946.USD","LU2125154778.USD","IXJ","LU1093756168.USD","LU0432979614.USD","XLV","BK4550","LU0985320562.USD","IE00BLSP4239.USD","LU0203347892.USD","SG9999014559.SGD","BK4007","LU0965509283.SGD","SG9999014575.USD","LU0266013472.USD","LU1201861249.SGD","LU2125909593.SGD","LU0130102774.USD","LU0289961442.SGD","LU1069347547.HKD","LU2023250843.SGD","BK4559","BMED","LU1989771016.USD","BK4516","MRK","LU1571399168.USD","LU1093756325.SGD","LU0980610538.SGD","LU2360032135.SGD","LU1941712264.USD","LU2324357040.USD","LU2361044949.HKD","LU2461242641.AUD","SG9999001176.USD","LU2089984988.USD","HRTS","LU0203345920.USD","LU1037948541.HKD","FTXH","LU1066053197.SGD","LU0070302665.USD","LU0859254822.USD","LU0106261372.USD","IE00BN8TJ469.HKD","LU0472753341.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667069643","title":"Bio-Techne Supplements Merger Proxy Amid Shareholder Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2667069643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667069643?lang=en_us&edition=fundamental","pubTime":"2026-09-15 05:35","pubTimestamp":1789421752,"startTime":"0","endTime":"0","summary":"Bio-Techne ( ($TECH) ) has shared an announcement. Bio-Techne Corporation, a Minnesota-based life sciences tools and diagnostics provider, supplies...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bio-techne-supplements-merger-proxy-amid-shareholder-litigation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bio-techne-supplements-merger-proxy-amid-shareholder-litigation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WDNA","RXL","CURE","RXD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695720","title":"Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695720","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695720?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:52","pubTimestamp":1789419160,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  said late Monday the phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for the treatment of major depressive disorder did not meet its primary efficacy endpoint.JNJ-5120/PIPE-307 is being developed by Johnson & Johnson  under a global license and development agreement, the company noted.The study evaluated improvement from baseline in the Montgomery-Asberg Depression Rating Scale total score at Day 5 compared with placebo, the company said, adding that the treatment was well tolerated and showed no new safety signals.Johnson & Johnson is continuing to review the trial data, including prespecified exploratory endpoints, to determine next steps for the program, according to a statement.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0289739343.SGD","LU0882574055.USD","GDOC","LU0289739699.SGD","LU2430703251.USD","CTNM","IXJ","LU0210536198.USD","IHE","LU0820561909.HKD","LU2129689431.USD","RXL","IE00BLSP4452.SGD","LU0124676726.USD","LU0466842654.USD","JNJ","LU0820561818.USD","XLV","LU2471134952.CNY","FTXH","LU2347655156.SGD","LU0162691827.USD","TRUH","JDOC","BK4534","PJP","BK4585","BMED","IE00B1BXHZ80.USD","LU1066051811.HKD","LU1929549753.HKD","LU0943347566.SGD","FHLC","LU0234570918.USD","LU2471134879.HKD","LU1244550494.USD","IE00BKVL7J92.USD","SG9999001176.USD","IYH","LU1629891620.HKD","IE0001KFT4U8.USD","LU1551013425.SGD","BK4581","MEDX","VHT","LU2471134523.USD","LU0058720904.USD","LU0426412945.USD","SG9999001440.SGD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667457695","title":"Medtronic PLC Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2667457695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667457695?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:38","pubTimestamp":1789418280,"startTime":"0","endTime":"0","summary":"DJ Medtronic PLC Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Medtronic PLC  advanced 3.12% to $93.80 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 0.48% to 7,619.98 and Dow Jones Industrial Average  falling 0.29% to 52,421.20.The stock's rise snapped a four-day losing streak.Medtronic PLC closed 11.78% below its 52-week high of $106.33, which the company reached on November 26th.The stock outperformed some of its competitors Monday, as Johnson & Johnson  rose 0.28% to $266.32, Danaher Corp.  rose 1.55% to $203.25, and Abbott Laboratories  rose 1.12% to $103.09.Trading volume  eclipsed its 50-day average volume of 7.5 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 14, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0069063385.USD","IE00BGHQF631.EUR","IYH","IE00B42XCP33.USD","MDT","LU2111349929.HKD","MEDX","GDOC","LU1935042991.SGD","LU0496365809.HKD","FHLC","TRUH","DHR","LU0289961442.SGD","LU1989764664.SGD","LU0234572021.USD","LU0472753341.HKD","IE0002141913.USD","JDOC","LU0320765489.SGD","FTXH","BMED","LU1721429402.USD","TMED","LU2028103732.USD","IE000BZT7R73.USD","RXL","IHI","IXJ","BK4568","IE0000B7K699.USD","XLV","IHE","SG9999001440.SGD","LU2089984988.USD","FMED","LU0109391861.USD","LU2468319806.SGD","ABT","LU2265009873.SGD","LU2456880835.USD","LU0203347892.USD","JNJ","VHT","LU0098860793.USD","LU2023250504.SGD","LU0106261372.USD","LU0053666078.USD","BK4532","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667869541","title":"Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2667869541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667869541?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:37","pubTimestamp":1789418272,"startTime":"0","endTime":"0","summary":"Niki BioSolutions Inc ( ($NIKI) ) just unveiled an announcement. Niki BioSolutions Inc operates in the biotechnology and molecular diagnostics sect...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/niki-biosolutions-highlights-strategic-synergies-in-alzheimers-diagnostics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/niki-biosolutions-highlights-strategic-synergies-in-alzheimers-diagnostics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","FWD","XT","GNMX","LNGR","JDOC","BBP","DARP","HELX","RSPH","SYNB","BK4588","IBB","IEIH","BMED","HTEC","FHLC","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695453","title":"Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695453?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:36","pubTimestamp":1789418160,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  rallied 1.87% to $146.41 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 0.48% to 7,619.98 and Dow Jones Industrial Average  falling 0.29% to 52,421.20.The stock's rise snapped a five-day losing streak.Gilead Sciences Inc. closed 6.92% below its 52-week high of $157.29, which the company achieved on February 11th.The stock outperformed some of its competitors Monday, as Johnson & Johnson  rose 0.28% to $266.32, Pfizer Inc.  remained unchanged, and Abbott Laboratories  rose 1.12% to $103.09.Trading volume  remained 1.5 million below its 50-day average volume of 6.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 14, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0859254822.USD","LU0965508806.USD","BK4585","LU0109394709.USD","LU0965509010.AUD","BBH","LU0823416689.USD","LU1778281490.HKD","IE00B3T34201.USD","LU0965509101.SGD","LU1066053197.SGD","LU2087621335.USD","BK4139","LU0320765992.SGD","LU1061106388.HKD","BK4568","LU1934455863.HKD","LU0861579265.USD","LU2357627491.SGD","SG9999015952.SGD","BK4532","LU1934455194.USD","LU1934455277.USD","MEDI","SG9999015986.USD","BK4583","BMED","LU1571399168.USD","IE00BSNM7G36.USD","IE0002270589.USD","BK4578","LU2112291526.USD","LU1674673428.USD","IE00B7SZLL34.SGD","BK4588","IBB","SG9999015945.SGD","LU1674673691.USD","BK4566","LU0965509283.SGD","IBBQ","LU1066051498.USD","LU0289739699.SGD","LU1839511570.USD","LU0122379950.USD","LU1057294990.SGD","BIB","LU0058720904.USD","BK4550","IE00BKVL7J92.USD","LU0114720955.EUR","LU0882574055.USD","LU1037948541.HKD","LU2089984988.USD","LU2324357040.USD","LU2468319806.SGD","LU1430594728.SGD","LU1037948897.HKD","GILD","LU1023059063.AUD","IE00BZ1G4Q59.USD","LU0234570918.USD","TMED","LU0889565916.HKD","SG9999015978.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695187","title":"Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695187","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695187?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:36","pubTimestamp":1789418160,"startTime":"0","endTime":"0","summary":"Shares of Contineum Therapeutics were trading lower after-hours Monday, following news a Phase 2 trial of an treatment for depression failed to meet its primary efficacy endpoint.Contineum said JNJ-5120/PIPE-307 is being developed by Johnson & Johnson under a global license and development agreement. The Phase 2 Moonlight-1 trial didn't meet its primary efficacy endpoint, although the treatment was well-tolerated with no new safety signals, the company added.Analyses of the data are ongoing, Contineum said.After the bell, shares of Contineum were trading 8.2% lower, at $13.59.  The stock ended the day's regular session flat, at $14.82.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","JNJ","IE0009355771.USD","IE00B19Z3B42.SGD","LU1162221912.USD","PJP","LU1674673691.USD","LU0345769128.USD","LU0820562030.AUD","LU0114720955.EUR","RXL","LU0426417589.USD","LU0994945656.USD","BMED","IE00BBT3K403.USD","SGXZ80539844.SGD","IE0002141913.USD","LU0210528500.USD","TRUH","IE00BLSP4452.SGD","IYH","CTNM","VHT","LU0943347566.SGD","FTXH","LU0792757196.USD","LU2430703251.USD","LU1551013342.USD","LU2456880835.USD","IE00BN8TJ469.HKD","XLV","FHLC","IE000BZT7R73.USD","LU0162691827.USD","IXJ","BK4559","IHE","JDOC","LU0057025933.USD","BK4550","LU0345770308.USD","LU0203345920.USD","IE00BGHQF631.EUR","LU1228905540.USD","LU2430703178.SGD","GDOC","LU2213496289.HKD","SG9999001176.USD","LU0124676726.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667769302","title":"Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2667769302","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667769302?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:11","pubTimestamp":1789416676,"startTime":"0","endTime":"0","summary":"Contineum, J&J's depression drug fails to meet mid-stage trial goalSept 15 (Reuters)-Contineum TherapeuticsCTNM.Osaid on Monday an experimental depression drug it developed with Johnson & JohnsonJNJ.Nfailed to meet the main goal of a mid-stage study.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4N4561IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1674673428.USD","IE00BN8TJ469.HKD","IE00BVYPNV92.GBP","LU1043141123.HKD","IYH","SGXZ57979304.SGD","IE00B3PB1722.GBP","IXJ","LU1074936037.SGD","LU1629891620.HKD","LU2592432038.USD","IE00B19Z3581.USD","LU0820561818.USD","LU1121112475.USD","IE00B3T34201.USD","MEDX","LU0234572021.USD","LU1894683348.USD","PJP","JDOC","FTXH","JNJ","IE00BDGV0183.EUR","VHT","BK4559","LU1196500208.SGD","LU0345769631.USD","IHE","LU2133065610.SGD","LU2236285917.USD","LU2505996509.AUD","IE000WAW04H5.SGD","LU2487616109.SGD","GDOC","CTNM","LU0912757837.SGD","LU1430594728.SGD","LU1894683264.USD","LU2129689605.HKD","FHLC","TRUH","XLV","LU2023250330.USD","RXL","LU2213496289.HKD","BMED","IE0009355771.USD","IE000M9KFDE8.USD","LU1929549753.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693701","title":"Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693701?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUABTMJR3:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0882574055.USD","IXJ","JNJ","LU0994945656.USD","LU2456880835.USD","SG9999001440.SGD","CTNM","IHE","LU0792757196.USD","LU2468319806.SGD","VHT","FTXH","GDOC","LU1066051498.USD","LU0345769128.USD","IE000BZT7R73.USD","LU1496350502.SGD","LU0289961442.SGD","LU1043141396.HKD","RXL","LU0234572021.USD","FHLC","IE0002141913.USD","LU1674673428.USD","IE00BGHQF631.EUR","XLV","LU0545562505.USD","LU0203347892.USD","BMED","LU0098860793.USD","MEDX","LU1935042991.SGD","LU0432979614.USD","LU0345770993.USD","LU0210536198.USD","IE0001KFT4U8.USD","BK4533","TRUH","IYH","LU0820562030.AUD","LU1674673691.USD","LU0072461881.USD","PJP","LU0053666078.USD","IE00B42XCP33.USD","LU1989771016.USD","LU1929549753.HKD","LU1145028129.USD","LU1043141123.HKD","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693306","title":"Merck & Co Exec Says Potential 340B and Policy Evolutions Would Create Tailwinds but are not Material to the Business - Morgan Stanley Conf","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693306?lang=en_us&edition=fundamental","pubTime":"2026-09-15 03:33","pubTimestamp":1789414394,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560EX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0859254822.USD","LU0965509010.AUD","LU1941712264.USD","LU0058720904.USD","LU1917777945.USD","LU1929549753.HKD","IE00B4R5TH58.HKD","LU0265550359.USD","LU1069347547.HKD","LU0124676726.USD","SG9999001440.SGD","LU2468319806.SGD","LU1066053197.SGD","LU0122379950.USD","LU2106854487.HKD","LU0320765646.SGD","LU0689626769.HKD","MRK","LU1061106388.HKD","IE000M9KFDE8.USD","LU0965509101.SGD","LU0266013472.USD","LU1989772923.USD","IE00BN8TJ469.HKD","LU0965509283.SGD","LU0648001328.SGD","LU2361044865.SGD","LU1116320901.HKD","LU1037948897.HKD","SG9999014542.SGD","IE0009355771.USD","PAWZ","LU1066051498.USD","LU1934455863.HKD","LU0203345920.USD","LU2360032135.SGD","SG9999014575.USD","LU0289739699.SGD","LU0203347892.USD","BK4550","BK4516","SG9999001176.USD","LU0432979614.USD","IHE","SG9999001176.SGD","XLV","LU2361045086.USD","LU0265550946.USD","LU0289961442.SGD","LU1116320737.USD","LU1291159041.SGD","LU2491050071.SGD","LU1162221912.USD","LU0472753341.HKD","IE00BLSP4239.USD","LU0208291251.USD","LU1941712348.USD","LU0069063385.USD","LU1699723380.USD","LU1989771016.USD","BK4007","LU0511384066.AUD","LU2125154935.USD","LU2023250843.SGD","IE0002141913.USD","LU2357627491.SGD","LU1974910355.USD","LU1571399168.USD","LU2361044949.HKD","LU0098860793.USD","SGXZ57979304.SGD","LU2125909593.SGD","BK4585","LU1057294990.SGD","LU1923622614.USD","TRUH","SG9999015358.SGD","IE00BSNM7G36.USD","LU0234572021.USD","IE00BFTCPJ56.SGD","LU0861579265.USD","LU2491050154.USD","SG9999002224.SGD","LU0965508806.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0006306889.USD","LU0823416689.USD","LU1037948541.HKD","LU0289739343.SGD","LU2461242641.AUD","SG9999014559.SGD","VHT","LU1066051225.USD","LU0985320562.USD","LU2023250504.SGD","LU1032466523.USD","IYH","LU1035773651.USD","LU2125909247.SGD","RXL","LU1989772840.SGD","LU1066051811.HKD","LU2433249047.HKD","PPH","HRTS","LU1023059063.AUD","BMED","FHLC","LU1934455194.USD","LU0868494708.USD","BK4533","JDOC","SG9999014567.USD","SG9999015341.SGD","FTXH","SG9999002232.USD","SG9999013999.USD","LU2125154778.USD","BK4559","GDOC","LU0057025933.USD","LU0868494617.USD","LU0238689110.USD","LU0106261372.USD","LU0477156953.USD","LU0980610538.SGD","LU1201861249.SGD","LU2089984988.USD","LU1934455277.USD","BK4588","IE00BJT1NW94.SGD","LU0320765489.SGD","LU1093756168.USD","IE00B1BXHZ80.USD","LU2112291526.USD","LU0130102774.USD","IE00B2B36J28.USD","LU0211331839.USD","LU1430594728.SGD","IE00BJJMRZ35.SGD","BK4534","LU1585245621.USD","LU0942090050.USD","LU0130517989.USD","LU1093756325.SGD","IXJ","LU0070302665.USD","LU2324357040.USD","LU1983299246.USD","LU2491049909.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}